Literature DB >> 25978958

Parthenolide prodrug LC-1 slows growth of intracranial glioma.

Joseph K Hexum1, Chani M Becker2, Aaron M Kempema1, John R Ohlfest3, David A Largaespada3, Daniel A Harki4.   

Abstract

LC-1 (also known as DMAPT or dimethylamino-parthenolide), a prodrug of parthenolide, was tested for anti-proliferative activity against glioma. LC-1 was found to have low micromolar cytotoxic activity against three glioma cell lines and was also found to be brain penetrant in healthy mice (2.1-3.0 brain-to-plasma ratio). In a syngeneic GL261 murine glioma model, LC-1 slowed tumor growth kinetics and extended the survival time of tumor-bearing mice in comparison to the vehicle control. Consequently, LC-1 represents a promising lead compound for further development as a glioma therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood–brain barrier; Glioblastoma; LC-1; Parthenolide; Pharmacokinetics

Mesh:

Substances:

Year:  2015        PMID: 25978958     DOI: 10.1016/j.bmcl.2015.04.058

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Authors:  Vikas Tyagi; Hanan Alwaseem; Kristen M O'Dwyer; Jessica Ponder; Qi Ying Li; Craig T Jordan; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2016-06-16       Impact factor: 3.641

2.  Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.

Authors:  Hanan Alwaseem; Benjamin J Frisch; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2017-08-08       Impact factor: 3.641

3.  Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.

Authors:  Aaron M Kempema; John C Widen; Joseph K Hexum; Timothy E Andrews; Dan Wang; Susan K Rathe; Frederick A Meece; Klara E Noble; Zohar Sachs; David A Largaespada; Daniel A Harki
Journal:  Bioorg Med Chem       Date:  2015-05-30       Impact factor: 3.641

Review 4.  Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties.

Authors:  Daniela Carlisi; Marianna Lauricella; Antonella D'Anneo; Anna De Blasio; Adriana Celesia; Giovanni Pratelli; Antonietta Notaro; Giuseppe Calvaruso; Michela Giuliano; Sonia Emanuele
Journal:  Biomedicines       Date:  2022-02-21

5.  Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.

Authors:  Sandeep Rana; Smit Kour; Yogesh A Sonawane; Caroline M Robb; Jacob I Contreras; Smitha Kizhake; Muhammad Zahid; Adam R Karpf; Amarnath Natarajan
Journal:  Chem Biol Drug Des       Date:  2020-04-22       Impact factor: 2.817

6.  Parthenolide: a novel pharmacological approach to promote nerve regeneration.

Authors:  Heike Diekmann; Dietmar Fischer
Journal:  Neural Regen Res       Date:  2016-10       Impact factor: 5.135

7.  ROS generation and autophagosome accumulation contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/MAPK signaling pathway and suppressing the Akt/mTOR signaling pathway.

Authors:  Yanjun Wang; Jiachen Zhang; Yihang Yang; Qian Liu; Guangming Xu; Rui Zhang; Qi Pang
Journal:  Onco Targets Ther       Date:  2019-03-07       Impact factor: 4.147

8.  Detyrosinated microtubules modulate mechanotransduction in heart and skeletal muscle.

Authors:  Jaclyn P Kerr; Patrick Robison; Guoli Shi; Alexey I Bogush; Aaron M Kempema; Joseph K Hexum; Natalia Becerra; Daniel A Harki; Stuart S Martin; Roberto Raiteri; Benjamin L Prosser; Christopher W Ward
Journal:  Nat Commun       Date:  2015-10-08       Impact factor: 14.919

9.  Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia.

Authors:  Xingjian Li; Daniel T Payne; Badarinath Ampolu; Nicholas Bland; Jane T Brown; Mark J Dutton; Catherine A Fitton; Abigail Gulliver; Lee Hale; Daniel Hamza; Geraint Jones; Rebecca Lane; Andrew G Leach; Louise Male; Elena G Merisor; Michael J Morton; Alex S Quy; Ruth Roberts; Rosanna Scarll; Timothy Schulz-Utermoehl; Tatjana Stankovic; Brett Stevenson; John S Fossey; Angelo Agathanggelou
Journal:  Medchemcomm       Date:  2019-08-01       Impact factor: 3.597

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.